公开(公告)号：WO2011022002A1

公开(公告)日：2011-02-24

申请号：PCT/US2009/054212

申请日：2009-08-18

Applicant: THE ROCKEFELLER UNIVERSITY ,  SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

Inventor： SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

IPC: C12N15/00 ,  A61K39/015

CPC classification number: A61K39/015 ,  A61K2039/5256 ,  A61K2039/55577 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/861 ,  C12N2710/10322 ,  C12N2710/10341 ,  C12N2710/10343 ,  Y02A50/412

Abstract: The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

Abstract translation: 本公开涉及腺病毒蛋白质修饰以增强对重组腺病毒转基因的免疫应答并规避预先存在的抗腺病毒免疫性。 一些实施方案涉及源自重组腺病毒质粒载体的重组腺病毒，其中重组腺病毒质粒载体包含编码与异源启动子和修饰的衣壳或核心蛋白可操作连接的疟原虫环子孢子蛋白或其抗原部分的核苷酸序列 其中将疟原虫环子孢子的免疫原性表位插入或取代至少部分衣壳或核心蛋白。 其他实施方案涉及包含根据上述实施方案的重组腺病毒的药物组合物或疟疾疫苗组合物。 其他实施方案包括治疗，预防或诊断疟疾的方法，其包括施用治疗量的根据上述实施方案的药物组合物或疟疾疫苗组合物。

公开(公告)号：WO2008133706A2

公开(公告)日：2008-11-06

申请号：PCT/US2007/082164

申请日：2007-10-22

Applicant: SCHERING CORPORATION ,  XOMA TECHNOLOGY LTD. ,  RAMACHANDRA, Sumant ,  BISHOP, Walter, Robert ,  MASAT, Linda ,  HUANG, Chao Bai

Inventor： RAMACHANDRA, Sumant ,  BISHOP, Walter, Robert ,  MASAT, Linda ,  HUANG, Chao Bai

IPC: A61K39/395

CPC classification number: C07K16/22 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro .

Abstract translation: 血管内皮生长因子（VEGF）过表达与涉及异常血管发生的多种病症有关。 本文公开了完全人抗体，其特异性结合人VEGF并抑制VEGF结合VEGF-R1和VEGF-R2，因此抑制VEGF信号传导。 基于其抑制VEGF信号传导的能力，本文公开的抗体可用于在体内和体外治疗血管生成和与血管发生相关的病症。

公开(公告)号：WO2008052005A3

公开(公告)日：2008-05-02

申请号：PCT/US2007/082286

申请日：2007-10-23

Applicant: SHENOGEN PHARMA GROUP LTD. ,  LI, Jin ,  MENG, Kun

Inventor： LI, Jin ,  MENG, Kun

IPC: A01N43/42 ,  A61K31/44

Abstract: Provided herein in certain embodiments are compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and/or treating diseases related to estrogen receptor alpha 36, for preventing and/or treating respiratory diseases such as asthma, for inducing cell death and/or inhibiting cell proliferation and for preventing and/or treating diseases involving abnormal cell proliferation such as cancers.

公开(公告)号：WO2005087250A1

公开(公告)日：2005-09-22

申请号：PCT/US2004/004142

申请日：2004-02-12

Applicant: NATIONAL INSTITUTES OF HEALTH ,  CSAKY, Karl, G. ,  KLEINMAN, Hynda ,  PONCE, Lourdes

Inventor： CSAKY, Karl, G. ,  KLEINMAN, Hynda ,  PONCE, Lourdes

IPC: A61K38/00

CPC classification number: A61K38/08 ,  A61K38/10 ,  C07K5/101 ,  C07K5/1016 ,  C07K14/78

Abstract: Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo . C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.

Abstract translation: 不规则的血管发生与多种病理状况有关。 肿瘤生长和转移取决于新血管的发育。 眼睛中新血管的发展或眼睛新生血管形成已经涉及各种严重的眼部疾病。 例如，脉络膜新生血管形成与年龄相关的黄斑变性相关，而视网膜新生血管形成与糖尿病性视网膜病变相关。 本发明基于肽体系C16Y的发现，C16Y抑制体内新生血管形成和肿瘤生长。 C16Y是来自层粘连蛋白-1的y1链的C16肽序列的加扰版本。 不同于作为血管生成刺激物的C16，C16Y已被证明可以抑制血管发生。 本发明公开了使用全长和截短版本的C16Y治疗眼新生血管形成和癌症的方法。

公开(公告)号：WO2004058801A2

公开(公告)日：2004-07-15

申请号：PCT/US2003/041053

申请日：2003-12-22

Applicant: CITY OF HOPE ,  ELLENHORN, Joshua, D., I. ,  DIAMOND, Don, J.

Inventor： ELLENHORN, Joshua, D., I. ,  DIAMOND, Don, J.

IPC: C07K

CPC classification number: C12N15/86 ,  A61K2039/5156 ,  A61K2039/55516 ,  A61K2039/55561 ,  A61K2039/57 ,  C07K14/4746 ,  C12N2710/24143 ,  Y10S435/81

Abstract: Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and/or CpG oligodeoxynucleotide immunomodulators.

Abstract translation: 已经在40-60％的人类癌症中观察到肿瘤抑制蛋白p53的突变。 这些突变通常与p53的高核和细胞质浓度相关。 由于许多肿瘤表现出高度升高的p53水平，蛋白质是癌症免疫治疗的有吸引力的靶标。 不幸的是，p53是一种自身抗原，可能被免疫系统的自身蛋白所耐受。 本发明基于这样的发现：通过施用含有编码p53（rMVAp53）的核酸的重组修饰的痘苗安卡拉（MVA）可以克服这种自身耐受性。 本发明公开了通过施用包含rMVAp53的组合物来产生对表达突变的p53的肿瘤细胞的p53特异性CTL应答的方法。 rMVAp53的给药减少了各种恶性细胞类型的肿瘤发展，肿瘤生长和死亡率。 通过施用CTLA-4阻断剂和/或CpG寡脱氧核苷酸免疫调节剂来增强这些作用。

公开(公告)号：WO2004027046A2

公开(公告)日：2004-04-01

申请号：PCT/US2003/029932

申请日：2003-09-19

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  HEINDEL, Ned, H. ,  HECK, Diane, E. ,  GUILLON, Christophe ,  RAPP, Robert, D. ,  LASKIN, Jeffrey, D.

Inventor： HEINDEL, Ned, H. ,  HECK, Diane, E. ,  GUILLON, Christophe ,  RAPP, Robert, D. ,  LASKIN, Jeffrey, D.

IPC: C12N

CPC classification number: C07D405/04 ,  C07D249/10 ,  C07D409/04 ,  C07D409/12 ,  C07D513/04 ,  C12Q1/6886

Abstract: This invention claims the process for producing two structural variants of functionalized 4-amino-3-mercapto-1,2,4-triazoles as inhibitors of nitric oxide synthase (NOS) and as inhibitors of malignant cell growth. This fundamental molecular construct operates as a heterocyclic mimic of the open-chain N-aminoarginines (or N-aminoguanidines) previously established as NOS inhibitors.

Abstract translation: 本发明要求保护作为一氧化氮合酶（NOS）抑制剂和作为恶性细胞抑制剂的功能化4-氨基-3-巯基-1,2,4-三唑的两种结构变体的方法 生长。 这种基本的分子构建体作为先前建立为NOS抑制剂的开链N-氨基精氨酸（或N-氨基胍）的杂环模拟物起作用。

公开(公告)号：WO2003065935A1

公开(公告)日：2003-08-14

申请号：PCT/US2003/003508

申请日：2003-02-05

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  KHAW, Kenneth

Inventor： KHAW, Kenneth

IPC: A61F2/06

CPC classification number: A61F2/954 ,  A61F2/856 ,  A61F2/958 ,  A61F2002/065 ,  A61F2250/006 ,  A61M25/0043 ,  A61M25/09 ,  A61M2025/0035 ,  A61M2025/0037

Abstract: The present invention is directed to an apparatus for and method of treatment or vascular procedures. An exitable lumen guide wire sheath (3) is disclosed and advantages thereof. The exitable lumen guide wire sheath (3) and method may be used as a multiple exitable lumen or single exitable lumen. A method of treatment of multiple branch vascular lesions is disclosed in which a desired branch of a multiple branch lesion may be protected for further procedures by an interventionalist or other practitioner. Other combinations and uses for the disclosed invention will be apparent to those skilled in the art.

Abstract translation: 本发明涉及用于治疗或血管手术的装置和方法。 公开了一种可出口管腔引导线护套（3）及其优点。 可出口管引导线护套（3）和方法可以用作多个可出口腔或单出口腔。 公开了治疗多个分支血管病变的方法，其中可以通过介入医生或其他从业者保护多支分支病变的期望分支进一步的手术。 所公开的发明的其它组合和用途对于本领域技术人员是显而易见的。

公开(公告)号：WO2003057450A1

公开(公告)日：2003-07-17

申请号：PCT/US2002/041511

申请日：2002-12-21

Applicant: GENERAL COMPONENTS, INC. ,  HO, David, Losan ,  FENG, Lianxun ,  DONG, Liqun ,  LIU, Xinhou ,  ZHEN, Zhen

Inventor： HO, David, Losan ,  FENG, Lianxun ,  DONG, Liqun ,  LIU, Xinhou ,  ZHEN, Zhen

IPC: B29C47/26

CPC classification number: B29C47/28 ,  B29C47/0014 ,  B29C47/065 ,  B29C47/128 ,  B29C47/26 ,  B29C47/268 ,  B29C47/705 ,  B29D11/00663 ,  B29L2011/0075

Abstract: A crosshead die (16) for a plastic optical fiber fabrication system (10) is provided. The crosshead die (16) includes a body (28), an insert (32), mounting flanges (58) on the upstream (25) and downstream end (26) for securing the crosshead die (16) to adjacent equipment or another crosshead dies (16), an axial bore (14) for receiving a mixed molten material that makes up the core, and a radial bore (36) for receiving a mixed molten material that makes up the outer layering material to be co-extruded over the core. The die insert (32) includes a material distribution channel system (70) that provides substantially the same linear distance for the mixed molten material to travel prior to the co-extrusion. If multiple die inserts are utilized, the crosshead die is able to co-extrude multiple layers over the core. If the crosshead dies are serially assembled, additional concentric layers of material can be co-extruded atop the layered plastic optical fiber extruded from the upstream crosshead die.

Abstract translation: 提供了一种用于塑料光纤制造系统（10）的十字头模具（16）。 十字头模具（16）包括主体（28），插入件（32），在上游（25）和下游端（26）上的安装凸缘（58），用于将十字头模具（16）固定到相邻的设备或另一个十字头 模具（16），用于接收构成芯的混合熔融材料的轴向孔（14）和用于接收构成外层材料的混合熔融材料的径向孔（36） 核心。 模具插入件（32）包括材料分配通道系统（70），其在共挤出之前提供与混合的熔融材料基本相同的线性距离以行进。 如果使用多个模具插入件，则十字头模具能够在芯上共挤出多个层。 如果十字头模具被串联组装，则可以在从上游十字头模头挤出的分层塑料光纤上共同挤出另外的同心层材料。

公开(公告)号：WO2003041568A2

公开(公告)日：2003-05-22

申请号：PCT/US2002/036837

申请日：2002-11-15

Applicant: UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY ,  HEWITT, Charles, W. ,  STRANDE, Louise ,  SCHUSTER, Kevin

Inventor： HEWITT, Charles, W. ,  STRANDE, Louise ,  SCHUSTER, Kevin

IPC: A61B

CPC classification number: C12N5/0068 ,  A61K35/12 ,  C12N5/0698 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/39 ,  C12N2501/395 ,  C12N2502/094 ,  C12N2502/1323 ,  C12N2533/56

Abstract: The primary aspect of the present invention it directed to a three-dimensional matrix, a living tissue equivalent, a tissue microarray, methods of making thereof, and methods of using thereof. In one embodiment of the invention, the three-dimensional matrix comprises fibroblasts and a fibrin matrix. In a preferred embodiment, the three-dimensional matrix comprises blood plasma, thrombin and fibroblasts. The three-dimensional matrix in accordance with this invention may be used to construct living tissue equivalents, including but not limited to skin, blood vessel, bone, tendon, ligaments, and organ equivalents, among many others. Furthermore, the living tissue equivalents may be used to test the effect of various agents and to study the mechanism of disease and the efficacy of various treatment protocols.

Abstract translation: 本发明的主要方面涉及三维基质，活组织当量，组织微阵列，其制备方法及其使用方法。 在本发明的一个实施方案中，三维基质包含成纤维细胞和纤维蛋白基质。 在优选的实施方案中，三维基质包括血浆，凝血酶和成纤维细胞。 根据本发明的三维基质可以用于构建活组织等同物，包括但不限于皮肤，血管，骨，腱，韧带和器官等同物等等。 此外，可以使用活组织等同物来测试各种药剂的作用并研究疾病的机制和各种治疗方案的功效。

公开(公告)号：WO2003022224A3

公开(公告)日：2003-03-20

申请号：PCT/US2002/028930

申请日：2002-09-11

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  O'CONNOR, Patrick, J.

Inventor： O'CONNOR, Patrick, J.

IPC: C12N15/00

Abstract: The invention relates to compositions and methods for enhancing bone healing, bone formation and wound healing. More specifically, it relates to the use of cyclooxygenase 2 (COX-2) following bone fracture, orthopaedic procedure or wound infliction to enhance healing.